Victory Capital Management
AGRX

Victory Capital Management’s Agile Therapeutics AGRX Stock Holding History

Victory Capital Management’s Portfolio AGRX Stock Details AGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-7
Closed -$7K – 2851
2021
Q4 		$7K Buy
7
+1
+17% +$1.41K ﹤0.01% 2751
2021
Q3 		$11K Buy
6
+1
+20% +$2.26K ﹤0.01% 2756
2021
Q2 		$14K Hold
5
– – ﹤0.01% 2720
2021
Q1 		$23K Sell
5
-1
-17% -$5.41K ﹤0.01% 2715
2020
Q4 		$32K Buy
+6
New +$35.3K ﹤0.01% 2483
2020
Q3 		– Sell
-6
Closed -$31K – 2581
2020
Q2 		$31K Buy
6
+1
+20% +$5.2K ﹤0.01% 2424
2020
Q1 		$18K Buy
+5
New +$28.7K ﹤0.01% 2887
2019
Q4 		– Sell
-4
Closed -$10K – 3488
2019
Q3 		$10K Buy
+4
New +$9.85K ﹤0.01% 3277

Other funds holding AGRX

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management's AGRX Position: Q1 2022 in Review

Victory Capital Management sold out of Agile Therapeutics (AGRX) in Q1 2022, closing a stake of 7 shares — an estimated $7K sold.

Victory Capital Management first reported a position in AGRX in Q3 2019 and held it in 8 quarters. The position peaked at $32K in Q4 2020. 36 funds tracked by Wall St. Rank hold AGRX as of Q1 2022.

  • Victory Capital Management reported no remaining Agile Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Victory Capital Management sold 7 Agile Therapeutics shares in Q1 2022, an estimated $7K.
  • Victory Capital Management first reported a position in Agile Therapeutics in Q3 2019 and held it in 8 quarters.
  • Victory Capital Management's Agile Therapeutics position peaked at $32K in Q4 2020.
  • 36 funds tracked by Wall St. Rank held Agile Therapeutics as of Q1 2022.

Based on Victory Capital Management's 13F filing for Q1 2022, filed 4 May 2022.